Abstract: The present disclosure is directed to methods of utilizing echocardiography for assessing hemodynamic significance of patent ductus arteriosus (PDA) at early time points to supplement a patient's clinical and laboratory data by determining a PDA severity score. The present disclosure is further directed to treating the patient for PDA based on the severity score.

Abstract: The invention relates to modified Factor IX coding sequence, expression cassette, vectors such as viral (e.g., lenti- or adeno-associated viral) vectors, and gene transfer methods and uses. In particular, to target Factor IX nucleic acid to cells, tissues or organs for expression (transcription) of Factor IX.

Abstract: Hematopoietic stem/progenitor cells (HSPC) and/or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.

Abstract: Compositions for the identification of patients at risk for the development of latent autoimmune diabetes, and methods of use thereof, for the diagnosis and treatment of the same.

Abstract: An orthopaedic device for securing between first and second regions of bone separated by a growth plate, the orthopaedic device comprising: a first portion to secure to a first fixing location on the first bone region; a second portion to secure to a second fixing location on the second bone region, the first fixing location and the second fixing location being laterally offset relative to a longitudinal axis of the bone; wherein the first and second portions are pivotally coupled between a first coupling location on the first portion and a second coupling location on the second portion such that movement of the first and second portions away from each other in a direction parallel to the longitudinal axis of the bone causes relative rotation of the first bone region and the second bone region thereby reducing the lateral offset of the first location and the second location.

Abstract: Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Abstract: A system for guiding a medical intervention is disclosed. The system employs a device guide that operates on the surface of a sphere that is centered on a selected target.

Abstract: A biometric sensor device system including a biometric sensor device, and a prediction computer. The biometric sensor device includes at least one camera, and a biometric sensor device processor configured to record a time synchronized communicative interaction between participants, by controlling at least one camera to record the participants over a time period, and transfer the recorded communicative interaction to the prediction computer. The prediction computer including a prediction computer processor configured to extract, from the recorded communicative interaction, a physical characteristic of each of the participants over the time period, compare the physical characteristic of at least one of the participants with the physical characteristic of at least another one of the participants over the time period, and classify or score at least one of the participants according to a predetermined classification or dimensional scoring scheme based on the comparison.

Abstract: A transcranial scanning device and method of use is disclosed. The transcranial scanning device is for identifying a neurologic-injury-mechanism and comprises a sensing wand comprising a transducer that produces and receives sound waves. The sensing wand is passed over a head of a patent with cerebral malaria, and sound waves reflect off of blood cells in blood vessels in the head of the patient creating an output sound wave responsive to a blood flow of the patient. The output sound wave is received by the transducer. An output screen coupled to the sensing wand, displays in real time an output waveform corresponding to the output sound wave, wherein the output waveform is indicative of one or more symptoms of cerebral malaria, and wherein said symptoms identify one or more neurologic-injury-mechanism occurring within the patient.

Abstract: The present disclosure relates to biomarker profiles and their use to predict a subject's response to an immunomodulatory treatment. Biomarkers in these profiles include cytokines and other proteins associated with the interleukin 1 family and the type 1 interferon family. Particular biomarkers include interleukin (IL)-2, soluble IL-2 receptor alpha (sIL-2RA), IL-5, IL-6, IL-9, IL-10, IL-18, IL-18 binding protein (IL-18BP), IL-18 receptor 1 (IL-18R1), IL-18 receptor accessory protein (IL-18RAP), IL-22, C-type lectin-like receptor (CD161), CD56, interferon gamma (IFN?), granulocyte macrophage colony stimulating factor (GM-CSF), serum amyloid A (SAA), and C-reactive protein (CRP). Particular biomarkers also include populations of cells including CD161+ cells and CD56+dim cells. The biomarker profiles can be used to predict a subject's responsiveness to an immunomodulatory treatment (e.g.

Abstract: Methods for preparing highly purified AAV vector formulations are provided. The highly pure AAV formulations described herein are superior for clinical use.

Abstract: A system and method for predicting risk of violence for an individual (primarily school violence, but not limited to school violence) performs the following steps: (a) receiving responses to questions from an individual; (b) extracting by a computerized annotator words or phrases from the questions and responses; (c) assigning by the annotator extracted word(s) or phrase(s) to at least one of a plurality of pre-defined categories; and (d) automatically identifying and scoring words or phrases that could be classified into the pre-defined categories by a trained machine-learning engine to produce a score reflecting relative risk of violence by the individual. The pre-defined categories include: expression of violent acts or thoughts of the individual; expression of negative feelings, thoughts or acts of others; expression of negative feelings, thoughts or acts of the individual; expression of family discord or tragedies; and expression of protective factors.

Abstract: Provided herein are engineered red blood cells expressing rare blood antigen group profiles, and methods of making use the same, are described. Also provided are recombinant reagent red blood cells that express or lack the expression of at least one protein (e.g., a blood group antigen) on its surface and uses thereof.

Abstract: Examples are described for dynamically applying a digital watermark to a file, such as a dataset of genomic sequencing data. In one example, a method of dynamically applying a watermark to at least a portion of a file includes generating a first random seed, generating an ordered pseudorandom set of integers, generating a second random seed, selecting, using the second random seed, a subset of the ordered pseudorandom set of integers, the subset corresponding to identifiers of data locations in the file, and modifying data at data locations in the file corresponding to at least a portion of the identifiers included in the subset to generate a watermarked file. The genomic data file may be an ordered Binary Alignment Map (BAM) file storing sequencing data or a Variant Call Format (VCF) file or a list of variants storing genomic variation data.

Abstract: A method for determining a presence of arthritis in a patient, including obtaining a first image of a patient's joint, wherein the first image is a visible light image, obtaining a second image of the patient's joint, wherein the second image is a thermal light image, determining an outline of the patient's joint from the first image, determining an outline of a reference area from the first image, wherein the patient's joint is adjacent to the reference area, determining a first representative topological temperature within the outline of the patient's joint of the first image from the second image, determining a second representative topological temperature within the outline of the reference area of the first image from the second image, comparing the first representative topological temperature and the second representative topological temperature; and determining a likelihood of the presence of arthritis within the patient's joint.

Abstract: Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to persistent multiple organ dysfunction syndrome (MODS) in pediatric patients following cardiopulmonary bypass (CPB). Certain aspects of the disclosure relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining one or more samples from a pediatric patient following CPB, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

Abstract: The present invention relates to methods for identifying an EoE endotype of a patient and treating the patient with one or more therapies targeted to the patient's disease endotype; and related methods for stratifying patients for clinical trials.

Abstract: Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.

Abstract: Identification of Fragile X syndrome (FXS) patients who are likely to respond to a treatment involving a GABAA receptor modulator (e.g., a selective GABAA receptor stimulator), for example, at a low dose, using peripheral Fragile X mental retardation protein (FMRP) as a biomarker, either taken alone or in combination with other biomarkers. Also provided here are methods for treating such FXS patients using the GABAA receptor modulator (e.g., a selective GABAA receptor stimulator at a low dose).

Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.